Skip to main content

08-09-2019 | Non-small cell lung cancer | Video | Article

Researcher comment: TMB does not predict NSCLC pembrolizumab–chemotherapy response

Corey Langer describes the findings from the KEYNOTE-021 exploratory analysis of the relationship between response to pembrolizumab plus chemotherapy and tumor mutational burden in metastatic non-small-cell lung cancer patients (7:35).

Read more about KEYNOTE-021 here

Back to the WCLC 2019 conference hub

Related topics

Image Credits